Toggle navigation EN

Publikationen 2011

  1. Brenneis C, Coste O, Altenrath K, Angioni C, Schmidt H, Schuh CD, Zhang DD, Henke M, Weigert A, Bruene B, Rubin B, Nüsing R, Scholich K, and Geisslinger G. Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J Biol Chem. 2011 Jan 21;286(3):2331-42
  2. Sam WJ, MacKey SC, Lötsch J, and Drover DR. Morphine and its metabolites after patient-controlled analgesia, considerations for respiratory depression. J Clin Anesth 2011 Mar;23(2):102-6
  3. Lötsch J and Geisslinger G. Pharmacogenetics of new analgescis. Br J Pharmacol 2011 Jun;163(3):447-60
  4. Doehring A, Geisslinger G, and Lötsch J. Epigenetics in pain and analgesia: An imminent research field. Eur J Pain 2011 Jan;15(1):11-6
  5. Ermer M and Harder S. Medication review of community-dwelling seniors using intensified home-care service. Int J Clin Pharm Ther 2011 Mar;49(3):179-84
  6. Holland S, Coste O, Zhang DD, Pierre SC, Geisslinger G and Scholich K. The ubiquitin ligase MYCBP2 regulates transient receptor potential vanilloid receptor 1 (TRPV1)-internalization through inhibition of p38 MAPK signaling. J Biol Chem 2011 Feb 4;286(5):3671-80
  7. Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem C, and Herrmann E. Impact of ribavirin on HCV replicon RNA decline during treatment with Interferon alfa and the protease inhibitors boceprevir or telaprevir. Antivir Ther 2011;16(5):695-704
  8. Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, Herrmann E, Lötsch J, and Berg T. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011 Mar;54(3):415-421
  9. Doehring A, Hofmann WP, Schlecker C, Zeuzem S, Sarrazin C, Berg T, Müller T, Herrmann E, Geisslinger G, and Lötsch J. Role of nucleoside transporter SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: Protection against anemia in chronic hepatitis C patients. Pharmacogenet Genomics  2011 Feb 19. [Epub ahead of print]
  10. Kallenborn-Gerhardt W and Schmidtko A. A novel signaling pathway that modulates inflammatory pain. J Neurosci 2011 Jan;31(3):798–800
  11. Niederberger E, Kynast K, Lötsch J and Geisslinger G. MicroRNAs as new players in the pain game. Pain 2011 Jul;152(7):1455-8
  12. Hummel T, Springborn M, Croy I, Kaiser J and Lötsch J. High pain sensitivity is distinct from high susceptibility to non-painful sensory input at threshold level. Int J Psychophysiol 2011 Apr;80(1):69-74
  13. Lötsch J. Genetic variability of pain perception and treatment – clinical pharmacological implications. Eur J Clin Pharmacol 2011 Feb 23 [Epub ahead of print]
  14. Meyer Dos Santos S, Klinkhardt U, Lang K, Parisius J, Kuczka K, and Harder S: Phenotypic differences of human neutrophils of carriers of the PSGL-1 A and B-allele in binding to immobilised P-selectin under flow conditions. Thrombosis Research 2011 Feb;127(2):105-10
  15. Tegeder I, Scheving R, Wittig I, Geisslinger G. SNOing at the nociceptive synapse? Pharmacol Rev 2011 Jun;63(2):366-89
  16. Doehring A, Küsener N, Flühr K, Neddermeyer T, Schneider G, and Lötsch J. Effect sizes in experimental pain produced by gender, genetic variants and sensitization procedures. PLoS One 2011 Mar 10;6(3):e17724
  17. Meyer dos Santos S, Klinkhardt U, Scholich K, Nelson K, Monsefi N, Deckmyn H, Kuczka K, Zorn A, and Harder S. The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glycoprotein Ib (GPIb). Blood May 5;117(18):4999-5008
  18. Tzvetkov MV, Saadatmand AR, Lötsch J, Tegeder I, Stingl JC, and Brockmöller J. Genetically polymorphic OCT1: Another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther 2011 Jul;90(1):143-50
  19. Gangadharan V, Wang R, Ulzhöfer B, Luo C, Bardoni R, Bali KK, Agarwal N, Tegeder I, Hildebrandt U, Nagy GG, Todd AJ, Ghirri A, Häussler A, Sprengel R, Seeburg PH, Macdermott AB, Lewin GR, Kuner R. Peripheral calcium-permeable AMPA receptors regulate chronic inflammatory pain in mice. J Clin Invest. 2011 Apr;121(4):1608-23
  20. Croy I, Springborn M, Lötsch J, Johnston ANB and Hummel T. Agreeable smellers and sensitive neurotics – about coherences between personality traits and sensory thresholds. PLoS One 2011 Apr 27;6(4):e18701
  21. Brecht K, Weigert A, Hu J, Popp R, Fisslthaler B, Korff T, Fleming I, Geisslinger G, Brüne B. Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2. FASEB J 2011 Mar 30. [Epub ahead of print]
  22. Revermann M, Mieth A, Popescu L, Paulke A, Wurglics M, Pellowska M, Fischer A, Steri R, Maier T, Schermuly R, Geisslinger G, Schubert-Zsilavecz M, Brandes R, Steinhilber D. A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine aortic aneurysm model. Br J Pharmacol 2011 Aug;163(8):1721-32
  23. Ulrych T, Böhm A, Polzin A, Daum G, Nüsing RM, Geisslinger G, Hohlfeld T, Schrör K, Rauch BH. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost 2011 Apr;9(4):790-8
  24. Olliges A, Wimmer S, Nüsing RM. Defects in mouse nephrogenesis induced by selective and non-selective cyclooxygenase-2 inhibitors. Br J Pharmacol 2011 Jul;163(5):927-36
  25. Felden L, Walter C, Harder S, Treede RD, Kayser H, Drover D, Geisslinger G, and Lötsch J. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. Br J Anaesth 2011 Sep;107(3):319-28
  26. Akimoto K, Klinkhardt U, Zeiher A, Niethammer M, Harder S: Anticoagulation with Argatroban for Elective Percutaneous Coronary Intervention: Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationship of Coagulation Parameters. J Clin Pharmacol 2011 Jun;51(6):805-18
  27. Rössig L, Genth-Zotz S, Rau M, Heyndrickx GR, Schneider T; Gulba DCL, Desaga M, Buerke M, Harder S, Zeiher AM. Anticoagulation with Argatroban for Elective Percutaneous Coronary Intervention: The ARG-E04 Multi-Center Study. Int J Cardiol 2011 Apr 14;148(2):214-219
  28. Holland S and Scholich K. Regulation of neuronal functions by the E3-ubiquitinligase Protein Associated with MYC (MYCBP2). Commun Integr Biol  2011 Sep;4(5):513-5
  29. Heine S, Michalakis S, Kallenborn-Gerhardt W, Lu R, Lim H, Weiland J, Del Turco D, Deller T, Tegeder I, Biel M, Geisslinger G, and Schmidtko A. CNGA3: A target of spinal NO/cGMP signaling and modulator of inflammatory pain hypersensitivity. J Neurosci 2011 Aug 3;31(31):11184-92
  30. Kühlein HN, Tegeder I, Möser C, Lim HY, Häussler A, Spieth K, Jennes I, Marschalek R, Beckhaus T, Karas M, Fauth M, Ehnert C, Geisslinger G, and Niederberger E. Nerve injury evoked loss of latexin expression in spinal cord neurons contributes to the development of neuropathic pain. PLoS One 2011 Apr 29;6(4):e19270
  31. Möser CV, Kynast K, Baatz K., Russe Q, Ferreirós N, Costiuk H, Lu RR, Schmidtko A, Tegeder I, Geisslinger G and  Niederberger E. The protein kinase IKKepsilon is a potential target for the treatment of inflammatory hyperalgesia. Journal of Immunology 2011 Sep 1;187(5):2617-25
  32. Lötsch J, Hofmann WP, Schlecker C, Zeuzem S, Geisslinger G, Ultsch A, and Doehring A. Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy. Pharmacogenomics 2011 Dec;12(12):1729-40
  33. Tsaur I, Makarević J, Hudak L, Juengel E, Kurosch M, Wiesner C, Bartsch G, Harder S, Haferkamp A, Blaheta RA. The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line.  Cancer Lett. 2011 Sep 3. [Epub ahead of print]
  34. Brenneis C, Sisignano M, Coste O, Altenrath K, Fischer MJ, Angioni C, Fleming I, Brandes RP, Reeh PW, Woolf CJ, Geisslinger G, and Scholich K. Soluble epoxide hydrolase limits mechanical hyperalgesia during inflammation. Mol. Pain 2011 Oct 4;7:78
  35. Wang Q, Birod K, Angioni C, Grösch S, Geppert T, Schneider P, Rupp M and Schneider G. Spherical harmonics coefficients for ligand-based virtual screening of cyclooxygenase inhibitors. PLoS ONE 2011;6(7):e21554.
  36. Lötsch J and Geisslinger G. Low-dose drug combinations along molecular pathways may maximize therapeutic effectiveness while minimizing collateral side-effects. Drug Discovery Today 2011  Dec;16(23-24):1001-6
  37. Lu R, Kallenborn-Gerhardt W, Geisslinger G, Schmidtko A. Additive antinociceptive effects of a combination of vitamin C and vitamin E after peripheral nerve injury. PLoS ONE  2011;6(12):e29240